-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

CAR-T and Other Cellular Therapy for Mutiple Myeloma

PhD Trainee
Program: Scientific Workshops @ ASH
Thursday, December 3, 2020: 9:12 AM-9:57 AM
Moderator:
Disclosures:
Shah: BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar: Research Funding; GSK, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx, Kite, Karyopharm: Consultancy.
NK cells, An Attractive Allogeneic Cell Source for Treatment of Multiple Myeloma

Michael O'Dwyer, MD

School of Medicine, National University of Ireland Galway, Galway, Ireland
Inventing the Future of Allogeneic CAR T-Cell Therapies through Gene Editing

Carrie Brownstein, MD

Cellectis, New York, NY
Novel Autologous Approaches to CAR T

Marcela V. Maus, MD, PhD

Massachusetts General Hospital, Boston, MA
Immune Profiling Responders vs. Non-Responders

Joseph Melenhorst, PhD

University of Pennsylvania, Philadelphia, PA
Clinical Laboratory Predictors of Durable Response

Sandy W. Wong, MD

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Panel Discussion & Live Q&A
See more of: Scientific Workshops @ ASH
<< Previous Session | Next Session >>